Is Pfizer Stock a Buy Now?
Last year, pharmaceutical giant Pfizer (NYSE: PFE) reported the highest revenue it had ever had in a single calendar year. But in 2023, the drugmaker has substantially underperformed the market, and its shares are down by 41% year to date. These two facts aren't unrelated. Pfizer generated record-breaking sales in 2021 and 2022 thanks to its coronavirus portfolio, which has lost momentum since the COVID-19 pandemic has largely receded.
Even so, investors could be underestimating Pfizer's potential. Let's find out why the healthcare giant is still worth investing in, especially at current levels.
Source Fool.com
Pfizer Inc. Stock
€21.81
0.460%
With 15 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
With a target price of 29 € there is a positive potential of 33.0% for Pfizer Inc. compared to the current price of 21.81 €.
